HK2 and neoplasm: A glucose metabolism advantage drives NSUN2 upregulation in tumor cells, which stabilizes key glycolytic gene transcripts (GLUT1, HK2, PFKM) via mRNA methylation, enhancing tumor cells’ competitive advantage in glucose uptake (75).